Hims & Hers Shares Plunge on FDA GLP-1 Crackdown and Novo Nordisk Lawsuit
Hims & Hers shares plunged after FDA announced plans to curb sales of compounded GLP-1 weight-loss products and Novo Nordisk filed a patent lawsuit over its pills. FDA warnings of 'decisive steps' against GLP-1 compounds boosted Novo Nordisk shares and underscored mounting legal and regulatory risks for Hims' distribution strategy.
1. Regulatory Crackdown on GLP-1 Compounds
The FDA announced intentions to restrict the sale of compounded GLP-1 weight-loss therapies, citing safety and efficacy concerns over unapproved formulations. Hims & Hers relies heavily on these compounds in its pharmacy segment, creating a significant bottleneck in its core growth strategy.
2. Novo Nordisk Patent Lawsuit
Novo Nordisk filed a patent lawsuit against Hims & Hers, alleging unauthorized use of its patented GLP-1 receptor agonist formulations in Hims' weight-loss pills. The legal action signals intensifying pressure on smaller distributors seeking to compete in the fast-growing GLP-1 market without licensing agreements.
3. Market Reaction
Hims & Hers stock tumbled, logging one of the session's steepest declines as investors reassessed its pharmacy model under regulatory and legal threat. Conversely, Novo Nordisk shares rose on expectations of potential royalty revenue and reinforced market leadership in GLP-1 therapies.